Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US chlamydia screening needs tighening, says CDC (US Centers for Disease Control and Prevention)

This article was originally published in Clinica

Executive Summary

The US Centers for Disease Control and Prevention (CDC) has recommended that all women with chlamydial infections be rescreened three to four months after treatment is completed. The added screening is part of the agency's 2002 guidelines for the treatment of sexually transmitted diseases (STDs). Chlamydia is the most common STD in the US with an estimated 15 million people infected every year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel